Altimmune (NASDAQ:ALT) Upgraded by Zacks Investment Research to Buy

Altimmune} stock has undergone multiple analysts rating changes in the recent past.  Altimmune Upgraded by Zacks Investment Research on 10-12-21. In a note to investors, the firm issued a new rating of Buy. The analysts previously had rating of Hold.

View More Altimmune (NASDAQ:ALT) Upgraded by Zacks Investment Research to Buy